From Yahoo Finance: 2025-05-22 17:25:00

BMO Capital Markets maintains an “Outperform” rating on Tourmaline Bio, Inc. (TRML) with a price target of $35, believing the market overreacted to Phase II data on Paci. They argue Paci has potential to be a best-in-class treatment despite concerns about CRP reduction and a COVID-related death.

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focusing on developing transformative medicines for immune and inflammatory diseases. BMO reviewed PK, PD, and safety data to support Paci’s unique profile. Despite potential, BMO suggests other AI stocks may offer higher returns with less risk than TRML.

If you are considering investing in TRML, BMO maintains a positive outlook on the company’s potential but suggests alternative AI stocks may offer greater returns with less risk. TRML focuses on developing medicines to treat immune and inflammatory diseases, with potential for growth in the biotechnology sector.

Read more: BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)